MANGALAM

Mangalam Drugs and Organics Share Price

 

Stock Hit Lower Circuit

 

Start SIP in MANGALAM

Start SIP

Performance

  • Low
  • ₹44
  • High
  • ₹44
  • 52 Week Low
  • ₹23
  • 52 Week High
  • ₹116
  • Open Price₹44
  • Previous Close₹47
  • Volume43,736
  • 50 DMA₹40.83
  • 100 DMA₹50.07
  • 200 DMA₹63.99

Investment Returns

  • Over 1 Month + 85.12%
  • Over 3 Month -34.84%
  • Over 6 Month -50.2%
  • Over 1 Year -56.58%

Smart Investing Starts Here Start SIP with Mangalam Drugs and Organics for Steady Growth!

Invest Now

Mangalam Drugs and Organics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -2.3
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 70
  • P/B Ratio
  • 0.6
  • Average True Range
  • 2.11
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 2.96
  • RSI
  • 61.8
  • MFI
  • 85.83

Mangalam Drugs and Organics Financials

Mangalam Drugs and Organics Technicals

EMA & SMA

Current Price
₹44.43
-2.33 (-4.98%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹40.31
  • 50 Day
  • ₹40.83
  • 100 Day
  • ₹50.07
  • 200 Day
  • ₹63.99

Resistance and Support

44.43 Pivot Speed
  • R3 44.43
  • R2 44.43
  • R1 44.43
  • S1 44.43
  • S2 44.43
  • S3 44.43

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Mangalam Drugs & Orgs. has an operating revenue of Rs. 238.42 Cr. on a trailing 12-month basis. An annual revenue de-growth of -14% needs improvement, Pre-tax margin of 2% needs improvement, ROE of 4% is fair but needs improvement. The company has a reasonable debt to equity of 6%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and around 25% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 7 which is a POOR score indicating inconsistency in earnings, a RS Rating of 4 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 62 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Mangalam Drugs and Organics Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-15 Quarterly Results
2025-11-20 Quarterly Results (Revised)
2025-09-05 Others Inter-alia to approve 1. Appointment of Secretarial Auditor for the period of 5 years 2. Re-appointment of Director who is retiring by rotation.
2025-08-07 Quarterly Results & Others To consider other business matters.
2025-05-17 Audited Results

Mangalam Drugs and Organics F&O

Mangalam Drugs and Organics Shareholding Pattern

35.64%
0%
0%
0.13%
0%
57.52%
6.71%

About Mangalam Drugs and Organics

  • NSE Symbol
  • MANGALAM
  • BSE Symbol
  • 532637
  • Chairman & Managing Director
  • Mr. Govardhan Murlidhar Dhoot
  • ISIN
  • INE584F01014

Similar Stocks to Mangalam Drugs and Organics

Mangalam Drugs and Organics FAQs

Mangalam Drugs and Organics share price is ₹44 As on 26 January, 2026 | 08:20

The Market Cap of Mangalam Drugs and Organics is ₹70.3 Cr As on 26 January, 2026 | 08:20

The P/E ratio of Mangalam Drugs and Organics is -2.3 As on 26 January, 2026 | 08:20

The PB ratio of Mangalam Drugs and Organics is 0.6 As on 26 January, 2026 | 08:20

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23